Cormorant Asset Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,790,462
| Closed | -$93M | – | 53 |
|
|
2024
Q3 | $93M | Hold |
2,790,462
| – | – | 4.93% | 4 |
|
|
2024
Q2 | $75.4M | Sell |
2,790,462
-562,679
| -17% | -$11.1M | 4.36% | 5 |
|
|
2024
Q1 | $72.4M | Buy |
3,353,141
+1,000,000
| +42% | +$21.8M | 3.18% | 9 |
|
|
2023
Q4 | $14.2M | Hold |
2,353,141
| – | – | 0.68% | 34 |
|
|
2023
Q3 | $13.1M | Hold |
2,353,141
| – | – | 0.76% | 32 |
|
|
2023
Q2 | $17.3M | Hold |
2,353,141
| – | – | 0.97% | 27 |
|
|
2023
Q1 | $9.44M | Buy |
2,353,141
+234,858
| +11% | +$1.15M | 0.62% | 39 |
|
|
2022
Q4 | $6.91M | Hold |
2,118,283
| – | – | 0.46% | 45 |
|
|
2022
Q3 | $7.88M | Sell |
2,118,283
-154,938
| -7% | -$572K | 0.55% | 45 |
|
|
2022
Q2 | $7.02M | Hold |
2,273,221
| – | – | 0.53% | 45 |
|
|
2022
Q1 | $12.1M | Hold |
2,273,221
| – | – | 0.93% | 30 |
|
|
2021
Q4 | $11.1M | Hold |
2,273,221
| – | – | 0.66% | 40 |
|
|
2021
Q3 | $20.2M | Sell |
2,273,221
-48,182
| -2% | -$444K | 0.82% | 35 |
|
|
2021
Q2 | $20.9M | Sell |
2,321,403
-34,597
| -1% | -$345K | 0.71% | 39 |
|
|
2021
Q1 | $37.2M | Buy |
+2,356,000
| New | +$38.5M | 0.83% | 32 |
|
Cormorant Asset Management's LBPH Position: Q4 2024 in Review
Cormorant Asset Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 2,790,462 shares — an estimated $93M sold.
Cormorant Asset Management first reported a position in LBPH in Q1 2021 and held it in 15 quarters. The position peaked at $93M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Cormorant Asset Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Cormorant Asset Management sold 2,790,462 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $93M.
- Cormorant Asset Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Cormorant Asset Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $93M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Cormorant Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.